NeuroSense Provides Business Update, Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
Portfolio Pulse from Happy Mohamed
NeuroSense Therapeutics announced the completion of patient enrollment in its Phase 2b ALS trial, with topline data expected in Q4 2023. The company is also preparing for a Phase 2 Alzheimer's Disease trial and reported positive results from a Parkinson's Disease biomarker study. Collaborations with Massachusetts General Hospital's NeuroEpigenetics Lab and QuantalX have been established.
June 01, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroSense completed patient enrollment in its Phase 2b ALS trial and is preparing for a Phase 2 Alzheimer's Disease trial. Positive results from a Parkinson's Disease biomarker study and collaborations with MGH NeuroEpigenetics Lab and QuantalX have been established.
The completion of patient enrollment in the Phase 2b ALS trial, preparation for the Phase 2 Alzheimer's Disease trial, positive results from the Parkinson's Disease biomarker study, and collaborations with MGH NeuroEpigenetics Lab and QuantalX indicate progress in NeuroSense's research and development efforts. These advancements are likely to have a positive short-term impact on NRSN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100